IBD patients have been found to have a higher risk of lymphoma.

Published Date: 26 Apr 2023

According to researchers from the Karolinska Institutet, patients with Crohn's disease and IBD have an elevated risk of developing lymphoma, and this risk has grown over the past few years.

Read Full News

Latest News

Blood Test Could Spot Gut Damage in Celiac Disease

A distinctive pattern of inflammatory proteins in the blood of adults with celiac disease reflects the severity of gut damage and may offer a noninvasive way to monitor disease activity.

Ustekinumab Biosimilar Switch Maintains Outcomes in Crohn's

Patients with Crohn's disease in remission who switch from reference ustekinumab to biosimilar versions maintain similar clinical success rates over 6 months to those continuing reference treatment.

Adding Radiotherapy to NAC Shows No Survival Benefit in PDAC

For patients with resectable pancreatic cancer, adding radiotherapy to neoadjuvant chemotherapy may improve pathological response, but that doesn’t translate into better outcomes.

Real-World Data Favor Upadacitinib in Bio-Exposed UC

A Portuguese real-world study finds that upadacitinib outperforms tofacitinib and ustekinumab — top-tier options after UC treatment failure — with higher remission rates at 16 and 52 weeks.

FDA Okays RAS Inhibitor Daraxonrasib for Pancreatic Cancer

Daraxonrasib is being hailed as a potential game changer for metastatic pancreatic cancer, roughly doubling survival vs chemotherapy in previously treated patients.

FDA Approves Zanidatamab Regimen for HER2-Positive GEA

Zanidatamab with tislelizumab and chemotherapy leads to overall survival of 26.4 months.

Todays Updates

Can 80 Gy Radiation Boost Survival in Prostate Cancer?

A modest increase in radiation dose improves progression-free survival over 10 years among men with high-risk prostate cancer — but the overall survival benefits found in a French trial are uncertain.

Todays Updates

Can 80 Gy Radiation Boost Survival in Prostate Cancer?

A modest increase in radiation dose improves progression-free survival over 10 years among men with high-risk prostate cancer — but the overall survival benefits found in a French trial are uncertain.

Latest News

A distinctive pattern of inflammatory proteins in the blood of adults with celiac disease reflects the severity of gut damage and may offer a noninvasive way to monitor disease activity.

Patients with Crohn's disease in remission who switch from reference ustekinumab to biosimilar versions maintain similar clinical success rates over 6 months to those continuing reference treatment.

For patients with resectable pancreatic cancer, adding radiotherapy to neoadjuvant chemotherapy may improve pathological response, but that doesn’t translate into better outcomes.

A Portuguese real-world study finds that upadacitinib outperforms tofacitinib and ustekinumab — top-tier options after UC treatment failure — with higher remission rates at 16 and 52 weeks.

Daraxonrasib is being hailed as a potential game changer for metastatic pancreatic cancer, roughly doubling survival vs chemotherapy in previously treated patients.

Zanidatamab with tislelizumab and chemotherapy leads to overall survival of 26.4 months.

News All Time

One Surgical Approach May Be Better for Complex Gallbladder Disease

Robotic cholecystectomy tied to reduced adverse outcomes over laparoscopic approach

You've Heard of Cyclospora. What Other Parasites Can You Catch From Food?

Experts describe some of the most common protozoa and worms

Iceberg Blamed in Diarrhea Outbreak; Masking Urged in Cities; DEA's Ketamine Probes

Health news and commentary gathered by MedPage Today staff

What's the Best Way to Test for Cyclospora Infection?

Microscopy and DNA tests are both viable, but sensitivity, cost, and availability vary

930 Dead in Outbreak; FDA Backtracks on Iceberg Lettuce; Chronic Cough Drug Fizzles

Health news and commentary gathered by MedPage Today staff

Novel Drug Shows Promise in Crohn's, Ulcerative Colitis

Duvakitug may be suitable for patients previously treated with advanced therapy

Inside the Intestinal Crypt: Untold Stories of Cyclospora

There's still much to learn about the parasite's past, present, and future

Lettuce Supplier Still the Focus in Cyclospora Outbreak, Despite Faulty Test Result

FDA says its investigation and outbreak data continue to point to Taylor Farms' iceberg lettuce

Singing for Chronic Belching; Excess Cancers in Crohn's; Dual Agonist for Liver Fat

News and commentary from the world of gastroenterology and hepatology

FDA Approves New Blood Test for Colon Cancer Screening

SimpleScreen CRC is indicated for adults 45 and up at average risk

Cyclospora Boosts Fears That Deadlier Foodborne Outbreaks Are Ahead

Food safety leaders across the U.S. are raising alarms over federal cuts

Intensified Pre-Op Chemoradiotherapy Fails in Locally Advanced Rectal Cancer

DFS at 3 years nearly identical with the addition of irinotecan, but with more toxicity

Diabetes and Pancreas Cancer; Crohn's Tied to Joint Infections; Hypnotherapy for IBS

News and commentary from the world of gastroenterology and hepatology

Michigan Reports First Two U.S. Deaths Related to Diarrhea-Causing Parasite

The CDC says cyclosporiasis is rarely deadly

FIT-Based Screening Linked to Drop in Colorectal Cancer Mortality

Inflection point occurred around 2012, 3 years after screening program was implemented

Study Examines Link Between IBD and Psychiatric Disorders

Does psychiatric morbidity precede IBD onset or arise after diagnosis?

Recommended News For You

Ruxolitinib Reduces Acute GVHD in Transplant Patients

Don't Call It Cancer; Clues to 'Exceptional' Responses; More Predictions for 2025

Immunotherapy-TACE Regimen Boosts PFS in Unresectable Liver Cancer

Research indicates that combining AI models enhances the ability to predict breast cancer risk.

Nirogacestat is approved by the FDA for treating rare non-cancerous soft tissue sarcomas.

Teclistamab Alone Ups Previously Treated Myeloma Survival

Indoor hydroponic gardening can improve mental health and quality of life for cancer patients

Recommended Articles For You

Unlocking the Secrets of Hemoglobin: How It Works to Keep Us Healthy 

Patient Management Following Organ-Preserving Cancer Interventions 

Unlocking the Potential of Pirtobrutinib: A New Frontier in Cancer Treatment 

Unlocking the Potential of Immune Checkpoint Inhibitors: A Pioneering Case Series on the Role of Immunotherapy in Microsatellite-Instability-High Colorectal Cancer 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A study on lung cancer provides additional proof of the value of screening.

2.

Enzalutamide vs Abiraterone: Which is Better for mCSPC?

3.

Is It Really Cancer? More Concerns About Accelerated Approval; Metformin and Cancer

4.

Germline Profiling May Improve Risk Stratification in t-MNs

5.

If CD19 CAR T-Cell Therapy Fails in Lymphoma, Try a CD22 Version

1.

Understanding Blood Dyscrasia: Symptoms, Causes and Treatment Options

2.

Unraveling the Mystery of Non-Caseating Granulomas: A Comprehensive Guide

3.

Case Study: Revolutionizing PNH Treatment with Eculizumab for Superior Patient Outcomes

4.

Practical Developments in Hematology in the Digital Era

5.

Advanced Pathways in Oncology for Better Care

1.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

2.

International Cancer Conference

3.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Navigating the Complexities of Ph Negative ALL - Part XI

2.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II

3.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI

4.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V

5.

Efficient Management of First line ALK-rearranged NSCLC - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot